Addressing RSV infection in older adults: implications for public health policy [0.03%]
老年人呼吸道合胞病毒感染的公共卫生政策应对措施
Floriana D&#x;Ambrosio,Marta Lomazzi,Michael Moore et al.
Floriana D&#x;Ambrosio et al.
Background: The rapid demographic shift toward an aging population presents growing challenges for health systems, particularly preventing infectious diseases. Respiratory syncytial virus (RSV), historically associated wi...
Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study [0.03%]
用于慢性阻塞性肺病患者的RSVPreF3佐剂疫苗接种率和效力：一项全国性丹麦队列研究
Maria João Fonseca,Stanislava Bratković,Yunus Çolak et al.
Maria João Fonseca et al.
Background: Individuals with chronic obstructive pulmonary disease (COPD) face increased risk of severe respiratory syncytial virus (RSV)-related outcomes. We assessed the uptake of adjuvanted-RSVPreF3 vaccine and its eff...
Vaccine hesitancy among 0-6-year-olds' guardians in Chongqing: a cross-sectional survey revealing how immunization program managers' robust comprehensive capacity for adverse events following immunization (AEFI) management mitigates hesitancy [0.03%]
重庆0至6岁儿童监护人群疫苗犹豫现状：一项横断面调查，揭示了免疫规划管理者强大的不良事件应对手段可缓解疫苗犹豫状况
Binyue Xu,Qing Wang,Jiawei Xu et al.
Binyue Xu et al.
Background: Vaccine hesitancy hinders optimal immunization coverage with fear of adverse events following immunization (AEFI) as a key driver. This study examines how robust district-level AEFI management capacity allevia...
Influenza vaccination willingness and influencing factors among older adults in Chongqing China: a cross-sectional study based on the WHO's behavioral and social drivers of vaccination framework [0.03%]
中国重庆市老年人流感疫苗接种意愿及影响因素调查——基于世卫组织疫苗接种行为与社会驱动模型框架的横断面研究
Jule Yang,Shuang Yang,Yu Xiong et al.
Jule Yang et al.
Background: In the context of China's aging population and low influenza vaccine coverage, this study applied the Behavioral and Social Drivers (BeSD) framework to investigate the willingness and determinants of influenza...
Preventing COVID-19 in at-risk populations: moving towards next-generation mRNA-1283 COVID-19 vaccine to address current challenges [0.03%]
预防高风险人群的COVID-19：迈向针对当前挑战的下一代mRNA-1283新冠疫苗
Joseph B Domachowske,Gregory D Zimet,William Hanage et al.
Joseph B Domachowske et al.
Introduction: Next-generation COVID-19 vaccines hold promise to reduce severe outcomes in populations most at risk. While the original mRNA COVID-19 vaccine, mRNA-1273, targets the full-length SARS-CoV-2 spike protein, mR...
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using a COVID-19 vaccine in Costa Rica [0.03%]
在哥斯达黎加使用COVID-19疫苗的接种策略的公共卫生和经济效益及成本效益模型分析
Juan José Baldi-Castro,Carlos Fernando Mendoza,Moe H Kyaw et al.
Juan José Baldi-Castro et al.
Background: Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. ...
Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions [0.03%]
查加斯病(Trypanosoma cruzi感染)疫苗的进展、挑战与未来方向
Eric Dumonteil,Claudia Herrera
Eric Dumonteil
Introduction: Chronic infections with Trypanosoma cruzi can lead to Chagas disease, with cardiac and/or digestive debilitating manifestations. There has been a renewed interest in vaccine development against this neglecte...
Correction [0.03%]
改正
Published Erratum
Expert review of vaccines. 2026 Dec;25(1):2629653. DOI:10.1080/14760584.2026.2629653 2026
A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China [0.03%]
中国减毒活疱疹疫苗（HZ/Oka）的安全性：自身前后对照病例系列研究
Xiang Cao,Mingwei Wei,Xiang Huo et al.
Xiang Cao et al.
Background: Herpes zoster (HZ), caused by varicella-zoster virus, primarily affects the elderly. In May 2023, the first domestically produced live attenuated zoster vaccine was approved for use in adults aged 40 years or ...
Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59 years at increased risk of severe RSV disease and those aged ≥60 years [0.03%]
针对增加患严重呼吸道合胞病毒(RSV)风险的日本50至59岁成人以及所有≥60岁成人，评估基于RSV 前融合F蛋白（RSVPreF3）疫苗附加佐剂的疫苗的有效性及降低危害程度的成本效益分析
Kentaro Tajima,Eleftherios Zarkadoulas,Joost Simons et al.
Kentaro Tajima et al.
Background: Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality in adults aged 50-59 years at increased risk of severe RSV disease due to specific underlying conditions (i.e. '50-59 years at-in...